Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists

EXTON, Pa., March 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that, despite the 2012 launch of Medivation/Astellas Pharma's Xtandi (enzalutamide) for the treatment of docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), surveyed oncologists report that Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga continues to dominate the second-line mCRPC setting—although its share dropped marginally from Q3 2012 to Q1 2013. The patient share of Sanofi's Jevtana showed a marked decline over this time period as a result of Xtandi's availability, especially in the third line where Jevtana's patient share in Q1 2013 is half that of its reported share in Q3 2012. The findings are from the TreatmentTrends^® Prostate Cancer (US) Q1 2013 report, in which 53 urologists and 51 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

"In the first-line symptomatic mCRPC setting, docetaxel still dominates treatment according to surveyed oncologists, despite the recent label extension of Zytiga for chemotherapy-naive mCRPC in December 2012," said Decision Resources Group Analyst Khurram Nawaz, M.Sc. "Nevertheless, surveyed oncologists indicate that Zytiga's patient share for first-line symptomatic mCRPC has almost doubled from Q3 2012 to Q1 2013. Interestingly, both surveyed urologists and oncologists indicate that Xtandi is also prescribed for first-line mCRPC patients, although this off-label use remains minimal due to perceived reimbursement challenges."

Surveyed physicians are most satisfied with Zytiga as a treatment for mCRPC; Dendreon's Provenge and mitoxantrone have the lowest levels of overall satisfaction. Satisfaction scores for the efficacy of therapies used to treat mCRPC are similar in Q1 2013 compared with prior waves of research; however, satisfaction with Xtandi in Q1 2013 is greater than the level of satisfaction with Zytiga in Q1 2012.

With respect to emerging therapies, improved efficacy is the most desirable attribute for emerging therapies in mCRPC, but sustained effects and long-term safety are also critical. On average, surveyed urologists more than oncologists prefer oral formulations and therapies that do not require monitoring. Surveyed physicians are more familiar with Algeta/Bayer HealthCare's radium-223 and Bristol-Myers Squibb's Yervoy than they are with other therapies in development for mCRPC. Surveyed physicians rate radium-223—which has been filed with the FDA and EMA, and granted priority review by the FDA—as the therapy in which they are most interested.

TreatmentTrends^® Prostate Cancer is a syndicated report designed to provide a view of the current and future management of prostate cancer based on primary research fielded with 50 urologists and 50 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Xtandi and potential launch of radium-223 through its LaunchTrends^® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at www.bio-trends.com.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597 
[email protected]

SOURCE BioTrends Research Group